Is AZT/3TC/NVP still the best choice? Clinical outcomes of antiretroviral therapy in Ugandan client cohort

Résumé fourni par la source

Background: Several studies have found that Tenofovir-containing regimens (TDF-CR) are associated with less drug substitution and better tolerance when compared with Zidovudine (AZT)-containing regimens. However, results on mortality and retention are conflicting, with some observational studies suggesting that AZT+Lamivudine(3TC)+Nevirapine (NVP) could be associated with better outcomes Conclusions: A strong association was found between receiving AZT+3TC+NVP during the first year of ART and better survival and retention compared with TDF-CR. Inferiority of TDF+3TC+NVP has been suggested in comparative studies before. For TDF+3TC+EFV, we hypothesized that in contexts like the one in our study, with limited access to investigations and reduced capacity to rule out opportunistic infections (OI), the increased potency of TDF+3TC+EFV to suppress viral replication (and therefore to cause more severe immune-reconstitution inflammatory syndrome (IRIS) in those with undetected OIs) could be one factor to explain its negative performance

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.